Hikma Pharmaceuticals Share News (HIK)

London close: Investors play it safe ahead of Fed meeting

(ShareCast News) - The selling pressure let up ahead of the start of a two-day policy meeting from the US Federal Reserve, with some investors braced in case the post-meeting statement sprang any surprises. The FTSE 100 finished the session higher by 0.77% to the 6,555.28 mark, alongside a similar b

LONDON MARKET CLOSE: Stocks Rebound; RSA Surges On Zurich's Interest

FTSE 100 movers: RSA rockets, Hikma higher

(ShareCast News) - London's primary index was holding onto its gain by mid-afternoon on Tuesday, boosted by deals and deal talk. At 1415 BST, the FTSE 100 was up 0.81% to 6,557.62, with only a dozen of the blue chip constituents in the red. As soon as markets opened, RSA Insurance moved to the top

UPDATE: Hikma Pharmaceuticals To Buy Roxane Units For USD2.65 Billion (ALLISS)

LONDON MARKET MIDDAY: US Stocks Seen Up Ahead Of Earnings, PMI Data

CORRECT: WINNERS & LOSERS SUMMARY: Zurich Interest Sends RSA Insurance Higher

UPDATE 2-Hikma to buy Boehringer's U.S. generic drug business for $2.65 bln

* To pay $1.18 bln in cash, issue 40 million new shares * Deal will make Hikma sixth biggest U.S. generics provider * Targeting 2017 revenue of $725 mln-$775 mln from units * Shares surge in London (Adds Hikma CEO, analyst comments) By Aastha Agnihotri and Roshni MenonRead more

TOP NEWS SUMMARY: UK Economic Growth Accelerates In Second Quarter

London open: Stocks bounce even as analysts warn on emerging markets

(ShareCast News) - The selling pressure on stocks abated as investors waited on the US Federal Reserve's policy announcement on Wednesday, but worries regarding the outlook for China, Greece and the possibility of interest rate increases were still very much on investors' minds. As of 08:47 the FTSE

LONDON MARKET MID-MORNING: Pound Surges After UK GDP Comes In-Line

WINNERS & LOSERS SUMMARY: Zurich Interest Sends RSA Insurance Higher

Hikma Pharmaceuticals acquires US labs in $2.25bn deal

(ShareCast News) - Drug developer Hikma Pharmaceuticals signed a deal to buy two firms from Boehringer Ingelheim in transactions worth a total of $2.25bn. FTSE 100 listed Hikma planned to buy Roxane Laboratories and associated company Boehringer Ingelheim Roxane in a cash and shares deal that would

BUZZ-Hikma: best day in 7 months after announcing Boehringer deal

** Hikma rises 6.7 pct after agreeing to buy Boehringer's specialty generics business for $2.65 bln in cash ** Valuation based on new Hikma shares priced at £23.50 ** Best day for stock since January 2015 ** Among top risers and most traded by average volumes on Stoxx 600 Read more

LONDON BRIEFING: Royal Mail Shares Hit By Ofcom Accusation

Hikma to buy Boehringer's U.S. generics unit for $2.65 bln

July 28 (Reuters) - Hikma Pharmaceuticals Plc said it would buy German drugmaker Boehringer Ingelheim's U.S. specialty generic drugs business for about $2.65 billion in cash and stock to bolster its presence in the United States. Hikma said it will pay about $1.18 billion in cash and issue